Jingfeng Pharmaceutical(SZ:000908) Zheng Quan Zhi Xing·2025-07-16 16:26Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., announces that part of the shares held by its controlling shareholder, Ye Xiangwu, will be subject to judicial enforcement due to a loan default, which will not affect the company's governance structure or operational status [1][3]. Group 1: Shareholder Information - Ye Xiangwu holds 120,902,286 shares, representing 13.74% of the company's total share capital [2]. - A total of 8,750,000 shares, accounting for 0.99% of the total share capital, will be disposed of through centralized bidding [1][2]. - The shares subject to enforcement are part of a pledge related to overdue loans provided as collateral to the Industrial and Commercial Bank of China [2][3]. Group 2: Judicial Enforcement Details - The enforcement period is set from July 22, 2025, to October 21, 2025 [1]. - The enforcement is based on a civil judgment that has already taken legal effect, concerning a financial loan dispute involving multiple parties, including the company and its subsidiaries [2][3]. - The company confirms that this share change does not violate any previously disclosed commitments or intentions [3]. Group 3: Company Governance and Compliance - The company assures that the judicial enforcement will not lead to a change in actual control or affect its production and operations [3]. - The board of directors will monitor the situation closely and ensure compliance with relevant laws and regulations during the enforcement period [4].